ELIZABETH A MCFARLAND

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family DOTHAN, AL NPI 1013551811

General Payments — all program years on this page

$1,890.60

  • Category: General Payments
  • Program years: PY2021–2024
  • Record count: 69
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $388.20 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $364.7816
Education $23.424

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2021 $449.1416
2022 $760.3419
2023 $292.9214
2024 $388.2020

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1119134456 Otsuka America Pharmaceutical, Inc. $22.90 10/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141519441 CALLIDITAS THERAPEUTICS US INC. $21.79 07/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1146736943 Ardelyx, Inc. $23.85 05/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1149952857 Travere Therapeutics, Inc. $0.37 09/20/2024 Education Undisputed 01/23/2026 View at CMS
1149952864 Travere Therapeutics, Inc. $3.08 01/25/2024 Education Undisputed 01/23/2026 View at CMS
1149952869 Travere Therapeutics, Inc. $3.08 02/29/2024 Education Undisputed 01/23/2026 View at CMS
1149952875 Travere Therapeutics, Inc. $16.89 02/29/2024 Education Undisputed 01/23/2026 View at CMS
1150698931 Aurinia Pharma U.S., Inc. $26.26 08/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154206752 Fresenius USA Marketing, Inc. $1.27 10/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154206754 Fresenius USA Marketing, Inc. $7.70 05/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154206756 Fresenius USA Marketing, Inc. $16.54 04/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154206758 Fresenius USA Marketing, Inc. $19.80 02/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154206760 Fresenius USA Marketing, Inc. $20.36 10/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154206762 Fresenius USA Marketing, Inc. $21.51 08/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154206764 Fresenius USA Marketing, Inc. $21.75 03/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154206766 Fresenius USA Marketing, Inc. $22.17 03/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154206768 Fresenius USA Marketing, Inc. $23.32 07/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154206770 Fresenius USA Marketing, Inc. $23.80 01/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154206772 Fresenius USA Marketing, Inc. $25.81 11/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154206774 Fresenius USA Marketing, Inc. $65.95 06/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.